O'Malley, D. M., Neffa, M., Monk, B. J., Melkadze, T., Huang, M., Kryzhanivska, A., . . . Lugowska, I. (2022). Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. Journal of clinical oncology, 40(7), 762. https://doi.org/10.1200/JCO.21.02067
Citácia podle Chicago (17th ed.)O'Malley, David M., et al. "Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study." Journal of Clinical Oncology 40, no. 7 (2022): 762. https://doi.org/10.1200/JCO.21.02067.
Citácia podľa MLA (8th ed.)O'Malley, David M., et al. "Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study." Journal of Clinical Oncology, vol. 40, no. 7, 2022, p. 762, https://doi.org/10.1200/JCO.21.02067.